Singha Manali, Pu Limeng, Srivastava Gopal, Ni Xialong, Stanfield Brent A, Uche Ifeanyi K, Rider Paul J F, Kousoulas Konstantin G, Ramanujam J, Brylinski Michal
Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA.
Center for Computation and Technology, Louisiana State University, Baton Rouge, LA 70803, USA.
Cancers (Basel). 2023 Aug 10;15(16):4050. doi: 10.3390/cancers15164050.
Deregulated protein kinases are crucial in promoting cancer cell proliferation and driving malignant cell signaling. Although these kinases are essential targets for cancer therapy due to their involvement in cell development and proliferation, only a small part of the human kinome has been targeted by drugs. A comprehensive scoring system is needed to evaluate and prioritize clinically relevant kinases. We recently developed CancerOmicsNet, an artificial intelligence model employing graph-based algorithms to predict the cancer cell response to treatment with kinase inhibitors. The performance of this approach has been evaluated in large-scale benchmarking calculations, followed by the experimental validation of selected predictions against several cancer types. To shed light on the decision-making process of CancerOmicsNet and to better understand the role of each kinase in the model, we employed a customized saliency map with adjustable channel weights. The saliency map, functioning as an explainable AI tool, allows for the analysis of input contributions to the output of a trained deep-learning model and facilitates the identification of essential kinases involved in tumor progression. The comprehensive survey of biomedical literature for essential kinases selected by CancerOmicsNet demonstrated that it could help pinpoint potential druggable targets for further investigation in diverse cancer types.
失调的蛋白激酶在促进癌细胞增殖和驱动恶性细胞信号传导中起着关键作用。尽管这些激酶由于参与细胞发育和增殖而成为癌症治疗的重要靶点,但人类激酶组中只有一小部分已被药物靶向。需要一个综合评分系统来评估临床相关激酶并确定其优先级。我们最近开发了CancerOmicsNet,这是一种利用基于图的算法来预测癌细胞对激酶抑制剂治疗反应的人工智能模型。该方法的性能已在大规模基准计算中进行了评估,随后针对几种癌症类型对选定预测进行了实验验证。为了阐明CancerOmicsNet的决策过程并更好地理解模型中每个激酶的作用,我们采用了具有可调通道权重的定制显著性图。显著性图作为一种可解释的人工智能工具,能够分析输入对训练后的深度学习模型输出的贡献,并有助于识别参与肿瘤进展的关键激酶。对CancerOmicsNet选择的关键激酶进行的生物医学文献综合调查表明,它有助于确定潜在的可成药靶点,以便在多种癌症类型中进行进一步研究。